A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases

Journal of Pharmaceutical Sciences

Volumn 99, Issue 5, 2010, Pages 2219-2239

  Choonara, Yahya E ^a   Pillay, Viness ^a   Danckwerts, Michael P ^a   Carmichael, Trevor R ^a   Du Toit, Lisa C ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Biodegradable polymers; Biomaterials; Bloodocular barriers; Device technology; Intravitreal implants; Localized drug delivery; Posterior segment eye disease; Vitreous humor

Indexed keywords

BETAMETHASONE; BIOMATERIAL; CIPROFLOXACIN; CONTRAST MEDIUM; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; ETHYLENE VINYL ACETATE COPOLYMER; EYE DROPS; FLUOCINOLONE ACETONIDE; FLUOROURACIL; GANCICLOVIR; GELFOAM; GENTAMICIN; HYALURONIC ACID; INSULIN; KETOTIFEN FUMARATE; LIPOSOME; MEDIDUR; MICROSPHERE; NANOSPHERE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; POLYOXYETHYLENE STEARYL ETHER; POLYVINYL ALCOHOL; RANIBIZUMAB; THALIDOMIDE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ANTERIOR EYE SEGMENT; BIODEGRADABLE IMPLANT; BLOOD EYE BARRIER; BLOOD RETINA BARRIER; CELL ENCAPSULATION; CHOROID; CLINICAL TRIAL; CONTACT LENS; DIABETIC MACULAR EDEMA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUTION; ELECTROLYSIS; ELECTRORETINOGRAPHY; ENDOTHELIUM CELL; EROSION; EYE DISEASE; EYE INFECTION; EYE INJURY; FLOW RATE; GRAVIMETRY; HUMAN; HYDROGEL; IMPLANT; INFLAMMATION; INTRAVITREAL DRUG ADMINISTRATION; IONTOPHORESIS; LIPOPHILICITY; MICROELECTROMECHANICAL SYSTEM; MOLECULAR WEIGHT; OPHTHACOIL; OSMOTIC MINIPUMP; PIGMENT EPITHELIUM; POSTERIOR SEGMENT EYE DISEASE; QUALITY OF LIFE; RECURRENCE RISK; RETINA BLOOD VESSEL; RETINA INJURY; REVIEW; SCLEROTOMY; SOLUBILITY; TABLET; UVEITIS; VASCULAR ENDOTHELIUM; VISCOSITY; VITREORETINOPATHY; VITREOUS HEMORRHAGE;

EID: 77951282109     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21987     Document Type: Review

References (139)

1. Bourges JL, Bloquel C, Thomas A, Froussart F, Bochot A, Azan F, Gurny R, BenEzra D, Behar-Cohen F. 2006. Intraocular implants for extended drug delivery: Therapeutic applications. Adv Drug Deliv Revs 58:1182-1202. (Pubitemid 44794429)
2. Velez G, Whitcup SM. 1999. New developments in sustained release drug delivery for the treatment of intraocular disease. Br J Ophthalmol 83:1225-1229. (Pubitemid 29511801)
3. Laties AM, Rapoport SI. 1976. The blood-ocular barriers under osmotic stress: Studies on the freeze-dried eye. Arch Ophthalmol 94:1086-1091.
4. Rapoport SI. 2000. Osmotic opening of the blood-brain barrier: Principles, mechanism, and therapeutic applications. Cell Mol Niurobiol 20:217-230.
5. Foulds WS, Moseley H, Eadie A, et al. 1980. Vitreal, retinal, and pigment epithelial contributions to the posterior blood-ocular barrier. Trans Ophthalmol Soc UK 100:341-342. (Pubitemid 11088094)
6. Cunha-Vaz JG. 1979. The blood-ocular barriers. Surv Ophthalmol 23:279-296.
7. Cunha-Vaz JG. 1997. The blood-ocular barriers: Past, present, and future. Doc Ophthalmol 93:149-157.
8. Ahmed I, Patton TF. 1986. Selective intraocular delivery of liposome encapsulated insulin via the non-corneal absorption route. Int J Pharm 34:163-167. (Pubitemid 17216792)
9. Schoenwald RD, Huang HS. 1983. Corneal penetration behavior of fl-blocking agents I: Physicochemical factors. J Pharm Sci 72:1266-1272. (Pubitemid 14229733)
10. Sieg JW, Robinson JR. 1977. Vehicle effects on ocular drug bioavailability II: Evaluation of pilocarpine. J Pharm Sci 66:1222-1228.
11. Liaw J, Robinson JR. 1992. The effect of polyethylene glycol molecular weight on corneal transport and the related influence of penetration enhancers. Int J Pharm 88:125-140. (Pubitemid 23000414)
12. Rojanasakul Y, Wang LY, Bhat M, Glover DD, Malanga CJ, Ma JKH. 1992. The transport barrier of epithelia: A comparative study on membrane permeability and charge selectivity in the rabbit. Pharm Res 9:1029-1034.
13. Schoenwald RD, Ward R. 1978. Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients. J Pharm Sci 67:786-788. (Pubitemid 8355235)
14. Chang SC, Lee VHL. 1987. Nasal and conjunctival contributions to the systemic absorption of topical timolol in the pigmented rabbits: Implications in the design of strategies to maximize the ratio of ocular to systemic absorption. J Ocul Pharmacol 3:159-169.
15. Brechu WF, Maren TH. 1993. pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors. Invest Ophthalmol Vis Sci 34:2581-2587.
16. Grass GM, Robinson JR. 1988. Mechanisms of corneal drug penetration II: Ultra-structural analysis of potential pathways for drug movement. J Pharm Sci 77:15-23.
17. Huang AJW, Tseng SCG, Kenyon KR. 1989. Paracellular permeability of corneal and conjunctival epithelia. Invest Ophthalmol Vis Sci 30:684-689.
18. Maren TH, Jankowska L. 1985. Ocular pharmacology of sulfonamides: The cornea as barrier and depot. Curr Eye Res 4:399-408. (Pubitemid 15123162)
19. Urtti A, Rouhiainen H, Kaila T, Saano V. 1994. Controlled ocular timolol delivery: Systemic absorption and intraocular pressure effects in humans. Pharm Res 11:1278-1282. (Pubitemid 24287406)
20. Charles JB, Ganthier R, Wilson MR, Lee DA, Baker RS, Leong KW, Glasgow BJ. 1991. Use of bioerodible polymers impregnated with mitomycin in glaucoma filtration surgery in rabbits. Ophthalmology 98:503-508.
21. Chang SC, Chien DS, Bundgaard H, Lee VHL. 1988. Relative effectiveness of prodrug and viscous solution approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol. Exp Eye Res 46:59-69.
22. Maurice D. 2001. Review: Practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther 17:393-401. (Pubitemid 32888812)
23. Visor GC. 1994. Drug design strategies for ocular therapeutics. Adv Drug Deliv Rev 14: 269-279. (Pubitemid 24189164)
24. Lang JC. 1995. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev 16:39-43.
25. Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R. 1998. Ophthalmic drug delivery systems-recent advances. Prog Retinal Eye Res 17: 33-58. (Pubitemid 28040752)
26. Oyster CW, Amthor FR, Takahashi ES. 1993. Dendritic architecture of on-off direction-selective ganglion cells in the rabbit retina. Vis Res 33: 579-608. (Pubitemid 23101907)
27. Mort M. 2000. Multiple modes of drug delivery. Mod Drug Discov 3:30-32.
28. Geroski DH, Edelhauser HF. 2001. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 52: 37-48. (Pubitemid 32973637)
29. Van Santvliet L, Ludwig A. 2004. Determinants of eye drop size. Surv Ophthalmol 49:197-213.
30. Hosoya T, Baccus SA, Meister M. 2005. Dynamic predictive coding by the retina. Am J Ophthalmol 140:969.
31. Gulsen D, Chauhan A. 2005. Dispersion of microemulsion drops in HEMA hydrogel: A potential ophthalmic drug delivery vehicle. Int J Pharm 292:95-117. (Pubitemid 40255792)
32. Choonara YE, Pillay V, Carmichael T, Danckwerts MP. 2006. An in vitro study of the design and development of a novel doughnut-shaped minitablet for intraocular implantation. Int J Pharm 310:15-24. (Pubitemid 43287963)
33. Choonara YE, Pillay V, Carmichael T, Danckwerts MP. 2007. Studies on a novel doughnut-shaped minitablet for intraocular drug delivery. AAPS PharmSciTech 8:1-7. (Pubitemid 351144581)
34. Hayreh SS. 1966. Posterior drainage of the intraocular fluid from the vitreous. Exp Eye Res 5:123-144.
35. Weiner AL. 1994. Polymeric drug delivery systems for the eye. In: Domb AJ, editor. Polymeric site specific pharmacotherapy. New York: John Wiley & Sons Ltd. pp. 316-346.
36. Kumar MNVR. 2000. Nano and microparticles as controlled drug delivery devices. J Pharm Pharmaceut Sci 3:234-258.
37. Chowhan M, Weiner AL, Bhagat H. 2002. Drug deliveryophthalmic route. In: Swarbrick J, Boylan JC, editors. Encyclopedia of pharmaceutical technology. New York: Marcel Dekker. pp. 863-870.
38. Ghate D, Edelhauser HF. 2006. Ocular drug delivery. Expert Opin Drug Deliv 3:275-287.
39. Duvvuri S, Majumdar S, Mitra AK. 2003. Drug delivery to the retina: Challenges and opportunities. Expert Opin Biol Ther 3:45-56. (Pubitemid 36193650)
40. Davis JL, Gilger BC, Robinson MR. 2004. Novel approaches to ocular drug delivery. Curr Opin Mol Therap 6:195-205.
41. Ludwig A. 2005. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Del Rev 57:1595-1639. (Pubitemid 41443472)
42. Hughes PM, Olejnik O, Chang TS, Lin JE, Wilson CG. 2005. Topical and systemic drug delivery to the posterior segments. Adv Drug Del Rev 57:2010-2032. (Pubitemid 41740793)
43. Heller J. 2005. Ocular delivery using poly(orto esters). Adv Drug Del Rev 57:2053-2062. (Pubitemid 41740796)
44. Edlund U, Albertsson AC. 2002. Degradable polymer microspheres for controlled drug delivery. In: Albertsson AC, editor. Advances in polymer science, Vol.157. Berlin: Springer-Verlag. pp. 68-112.
45. Lloyd AW, Faragher RGA, Denyer SP. 2001. Ocular biomaterials and implants. Biomaterials 22:769-785.
46. Diebol Y, Jarrin M, Saez V, Carvalho ELS, Orea M, Calonge M, Seijo B, Alonso MJ. 2007. Ocular drug delivery by liposomechitosan nanoparticle complexes (LCS-NP). Biomaterials 28:1553-1564. (Pubitemid 46027250)
47. Moritera T, Ogura Y, Honda Y, Wada R, Hyon SH, Ikada Y. 1991. Microspheres of biodegradable polymers as a drug delivery system in the vitreous. Invest Ophthalmol Vis Sci 32:1785-1790.
48. Veloso AA, Zhu Q, Herrero-Vanrell R, Refojo MF. 1997. Ganciclovir- loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus. Invest Ophthalmol Vis Sci 38:665-675. (Pubitemid 27143138)
49. Ambati J, Gragoudas ES, Miller JW, You TT, Miyamoto K, Delori FC, Adamis AP. 2000. Transcleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci 41:1186-1191. (Pubitemid 30187559)
50. Ogura Y, Guran T, Mori MT, Takahashi K, Zeimer R. 1993. Occlusion of retinal vessels using targeted delivery of a platelet aggregating agent. Br J Ophthalmol 77:233-237. (Pubitemid 23133035)
51. Sanborn GE, Anand R, Torti RE, Nightingale SD, Cal SX, Yates B, Ashton P, Smith T. 1992. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Arch Ophthalmol 110: 188-195.
52. Martin DF, Kupperman BD, Wolitz RA, Palestine AG, Li H, Robinson CA. 1999. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med 340:1063-1070. (Pubitemid 29162510)
53. Martin DF, Parks DJ, Mellow SD, et al. 1994. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: A randomized controlled clinical trial. Arch Ophthalmol 112:1531-1539.
54. Benz MS, Albini TA, Holz ER, Lakhanpal RR, Westfall AC, Iyer MN, Carvounis PE. 2006. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 113:1174-1178. (Pubitemid 43947221)
55. Yang CS, Khawly JA, Hainsworth DP, Chen SN, Ashton P, Guo H, Jaffe GJ. 1998. An intravitreal sustained-release triamcinolone and 5-fluorouracil co-drug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 116:69-77. (Pubitemid 28098896)
56. Akula SK, Peyman GA, Rahimy MH, Hyslop NE, Janney A, Ashton P. 1994. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. Br J Ophthalmol 78:667-680. (Pubitemid 24275551)
57. Smith TJ, Pearson PA, Blanford DL, Brown JD, Goins KA. 1992. Intravitreal sustained-release ganciclovir. Arch Ophthalmol 110:255-258.
58. Heinemann MH. 1989. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol 107:1767-1772. (Pubitemid 20013138)
59. Yoon SJ, Rhee DY, Marx JL, Blaha GR, Rogers AH, Baumal CR, Rachel E, Duker JS. 2009. Anatomic and visual outcomes of noninfectious endophthalmitis after intravitreal triamcinolone. Am J Ophthalmol 147:1031-1036.
60. Herroro-Vanrell R, Ramirez L, Fernandaz-Carallido A, et al. 2000. Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process. Pharm Res 17:1323-1328.
61. Cheng L, Hostetler K, Chaidhawangul S, Gardner MF, Beadle JR, Toyoguchi M, et al. 2002. Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-o-hexadecylpropanediol-3-phopho- ganciclovir. Invest Ophthalmol Vis Sci 43:515-521. (Pubitemid 34113237)
62. Cheng L, Hostetler KY, Chaidhawangul S, Gardner MF, Beadle JR, Keefe KS, Bergeron-Lynn G, et al. 2000. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Invest Ophthalmol Vis Sci 41:1523-1532. (Pubitemid 30261879)
63. Merodio M, Irache JM, Valamanesh F, Mirshahi M. 2002. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials 23:1587-1594. (Pubitemid 34158581)
64. Yasukawa T, Ogura Y, Sakurai E, Tabata Y, Kimura H. 2005. Intraocular sustained drug delivery using implantable polymeric devices. Adv Drug Del Rev 57:2033-2046. (Pubitemid 41740794)
65. Bonferoni MC, Chetoni P, Giunchedi P, Rossi S, Ferrari F, Burgalassi S, Caramella C. 2004. Carrageenan-gelatin mucoadhesive systems for ion-exchange based ophthalmic delivery: In vitro and preliminary in vivo studies. Eur J Pharm Biopharm 57:465-472.
66. Kassem MA, Rahman AAA, Ghora MM, Ahmed MB, Khalil RM. 2007. Pharmaceutical nanotechnology nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 340:126-133.
67. Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. 2008. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimization and in vitro characterization. Eur J Pharm Biopharm 68:513-525. (Pubitemid 351318222)
68. Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R. 1998. Ophthalmic drug delivery systems-recent advances. Prog Retinal Eye Res 17:33-58. (Pubitemid 28040752)
69. Martinez-Sancho C, Herrero-Vanrell R, Negro S. 2004. Optimization of acyclovir poly(D,L-lactide-co-glycolide) microspheres for intravitreal administration using a factorial design study. Int J Pharm 273:45-56. (Pubitemid 38317039)
70. Kimura H, Ogura Y, Hashizoe M, Nishiwaki H, Honda Y, Ikada Y. 1994. A new vitreal drug delivery system using an implantable biodegradable polymeric device. Invest Ophthalmol Vis Sci 35:2815-2819. (Pubitemid 24149795)
71. Kimura H, Ogura Y, Moritera T, Honda Y, Wada R, Hyon SH, Ikada Y. 1992. Injectable microspheres with controlled drug release for glaucoma filtering surgery. Invest Ophthalmol Vis Sci 33:3436-3441.
72. Moritera T, Ogura Y, Yoshimura N, Honda Y, Wada R, Hyon SH, Ikada Y. 1992. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 33:3125-3130.
73. Hickey T, Kreutzer D, Burgess DJ, Moussy F. 2002. Dexamethasone/ PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials 23: 1649-1656. (Pubitemid 34158587)
74. Ashton P. 2000. Sustained-release inserts help deliver intraocular drugs. (Brief article) (Column) Ophthalmol Times, May.
75. Ashton P, Brown JD, Pearson PA. 1992. Intravitreal ganciclovir pharmacokinetics in rabbits and man. J Ocular Pharmacol 8:343-347. (Pubitemid 23040170)
76. Sultana Y, Jain R, Aqil M, Ali A. 2006. Review of ocular drug delivery. Curr Drug Deliv 3:207-217.
77. Herrero-Vanrell R, Refojo MF. 2001. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Del Rev 52:5-16. (Pubitemid 32973634)
78. Danckwerts MP, Fassihi A. 1991. Implantable controlled release drug delivery systems: A review. Drug Dev Ind Pharm 17:1465-1502.
79. Musch DC, Martin DF, Matthew D, Davis MD, Kupperman BD, Gordon JF. 1997. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 337:83-90. (Pubitemid 27284393)
80. Zaheer S, Lehman J, Stevenson G. 1982. Capsular contracture around silicone implants: The role of intraluminal antibiotics. Plast Recon Surg 69:809-812. (Pubitemid 12115946)
81. Park H, Park K. 1996. Biocompatibility issues of implantable drug delivery systems. Pharm Res 13:1770-1776. (Pubitemid 27034106)
82. Wood DA. 1980. Biodegradable drug delivery systems. Int J Pharm 7:1-18.
83. Lewis DH. 1990. Controlled release of bioactive agents from lactide/glycolide polymers. In: Chasin M, Langer R, editors. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker. pp. 1-41.
84. Graham NB. 1978. Polymeric inserts and implants for the controlled release of drugs. Br Polym J 10:260-266.
85. Dash AK, Cudworth GC II. 1998. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods 40:1-12. (Pubitemid 29062900)
86. Pijls RT, Sonderkamp T, Daube GW, Krebber R, Hanssen HHL, Nuijts RMMA, Koole LH. 2005. Studies on a new device for drug delivery to the eye. Eur J Pharm Biopharm 59:283-288. (Pubitemid 40127585)
87. Pijls RT, Cruysberg LPJ, Nuijts RMMA, Dias AA, Koole LH. 2007. Capacity and tolerance of a new device for ocular drug delivery. Int J Pharm 341:152-161.
88. Parks DJ, Abrams DA, Sarfarazi FA, Katz HR. 1993. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. Am J Ophthalmol 115:471-477.
89. Rosemary MJ, Suryanarayanan V, Reddy G, Maclaren I, Baskaran S, Pradeep T. 2003. Ciprofloxacin@SiO2: Fluorescein nanobubbles. Proc Indian Acad Sci (Chem Sci) 115:703-709.
90. Iyer SA, Tuli SS, Wagoner RC. 2006. Fungal keratitis: Emerging trends and treatment outcomes. Eye Contact Lens 32:267-271. (Pubitemid 44747199)
91. Pijls RT, Hanssen HHL, Nuijts RMMA, Daube GW, Koole LH. 2006. In vivo tolerance and kinetics of a novel ocular drug delivery device. J Control Rel 116:e47-e49.
92. Ali M, Horikawa S, Venkatesh S, Saha J, Hong JW, Byrne ME. 2007. Zero-order therapeutic release from imprinted hydrogel contact lenses within in vitro physiological ocular tear flow. J Control Rel 124:154-162. (Pubitemid 350110488)
93. Gilger BC, Malok GE, Stewart T, Horohov D, Ashton P, Smith T, Jaffe GJ, Allen JB. 2000. Effect of an intravitreal cyclosporine implant on experimental uveitis in horses. Vet Immunol Immunopathol 76:239-255.
94. Jaffe GJ, Yang CS, Wang XC, Cousins SW, Gallemore RP, Ashton P. 1998. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology 105: 46-56. (Pubitemid 28070601)
95. Lee Y, Yalkowsky SH. 1999. Effect of formulation on the systemic absorption of insulin from enhancer-free ocular devices. Int J Pharm 185: 199-204. (Pubitemid 29392906)
96. Lee Y, Simamora P, Yalkowsky SH. 1997. Effect of Brij-78 on systemic delivery of insulin from an ocular device. J Pharm Sci 86:430-433. (Pubitemid 27154756)
97. Lee Y, Simamora P, Yalkowsky SH. 1997. Systemic delivery of insulin via an enhancer-free ocular device. J Pharm Sci 86:1361-1364. (Pubitemid 28018314)
98. Yamamoto A, Luo AM, Dodda-Kashi S, Lee VHL. 1989. The ocular route for systemic insulin delivery in the albino rabbit. J Pharm Exp Ther 249:249-255. (Pubitemid 19115816)
99. Chiou GCY, Chuang CY. 1989. Improvement of systemic absorption of insulin through eyes with absorption enhancers. J Pharm Sci 78:815-818.
100. Chiou GCY, Shen ZF, Zheng YQ. 1990. Adjustment of blood sugar levels with insulin and glucogon eyedrops in normal and diabetic rabbits. J Ocul Pharmacol 3:233-241.
101. Chiou GCY. 1991. Systemic delivery of polypeptide drugs through ocular route. Ann Rev Pharmacol Toxicol 31:467-475.
102. Hopper PE, Murphy CJ, Feldman EC, Chiou GCY, Li BPH. 1993. Chronic systemic delivery of insulin through the ocular route. J Ocul Pharmacol 9:85-89.
103. Bartlett JD, Slusser TG, Turner-Henson A, Singh K, Atchison JA, Pillion DJ. 1994. Toxicity of insulin administration chronically to human eye in vivo. J Ocul Pharmacol 10:101-107. (Pubitemid 24119434)
104. Bartlett JD, Turner-Henson A, Atchison JA, Woolley TW, Pillion DJ. 1994. Insulin administration to the eyes of normoglycemic human volunteers. J Ocul Pharmacol 10:683-690.
105. Sasaki H, Tei C, Yamamura K, Nishida K, Nakamura J. 1994. Effect of preservatives on systemic delivery of insulin by ocular instillation in rabbits. J Pharm Pharmacol 46:871-875. (Pubitemid 24350860)
106. Sasaki H, Tei C, Nishida K, Nakamura J. 1995. Effect of ophthalmic preservatives on serum concentration and local irritation of ocularly applied insulin. Biol Pharm Bull 18:169-171.
107. Pillion DJ, Recchia J, Wang P, Marciani DJ, Kensil CR. 1995. DS-1, a modified quillaja saponin, enhances ocular and nasal absorption of insulin. J Pharm Sci 84:1276-1279.
108. Morgan RV. 1995. Delivery of systemic regular insulin via the ocular route in cats. J Ocul Pharmacol 11:565-573.
109. Simamora P, Lee YC, Yalkowsky SH. 1996. Ocular device for the controlled systemic delivery of insulin. J Pharm Sci 85:1128-1130. (Pubitemid 26338931)
110. Morgan RV, Huntzicker MA. 1996. Delivery of systemic regular insulin via the ocular route in dogs. Ocul Pharmacol 12:515-526. (Pubitemid 26405756)
111. Negvesky GJ, Butrus SI, Farah A, Lee YC, Yalkowsky SH. 1999. Gelfoam disc ocular inserts for pupillary dilation in human eyes. The Association for Research in Vision and Ophthalmology (ARVO), Annual Meeting, Fort Lauderdale, FL, pp. S.85. Abstract 53042.
112. Lee YC, Yalkowsky SH. 1999. Ocular devices for the controlled systemic delivery of insulin: In vitro and in vivo dissolution. Int J Pharm 181:71-77.
113. Lim JL, Wolitz RA, Dowling AH, Bloom HR, Irvine AR, Schwarz DM. 1999. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 127:288-293.
114. Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P. 2000. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 107:2024-2033.
115. Jaffe GJ, Pearson PA, Ashton P. 2000. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina 20:402-403.
116. Yang CS, Khawly JA, Hainsworth DP, Chen SN, Ashton P, Guo H, Jaffe GJ. 1998. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 116:69-77. (Pubitemid 28098896)
117. Kuppermann BD. 2006. Implant delivery of corticosteroids and other pharmacologic agents. Presented at Retina 2006: Emerging New Concepts. Held in conjunction with the American Academy of Ophthalmology 2006 Annual Meeting, November 10-11, 2006, Las Vegas.
118. Li PY, Shih J, Lo R, Adams B, Agrawal R, Saati S, Humayun MS, Tai YC, Meng E. 2007. An electrochemical intraocular drug delivery device, In: Proceedings of the 20th IEEE International Conference on Micro Electro Mechanical Systems, Kobe, Japan, 21-25 January, 2007, pp. 15-18.
119. Belmont C, Girault HH. 1994. Coplanar interdigitated band electrodes for electrosynthesis. Part 2. Methoxylation of furan. J Appl Electrochem 24:719-724.
120. Yasukawa T, Kimura MDH, Tabat Y, Ogura Y. 2001. Biodegradable scleral plugs for vitreoretinal drug delivery. Adv Drug Deliv Rev 52:25-36. (Pubitemid 32973636)
121. Ogura Y, Ikada Y. 1998. Biodegradable scleral plug. US Patent 5,707,643.
122. Kunou N, Ogura Y, Hashizoe M, Honda Y, Hyon SH, Ikada Y. 1995. Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J Control Rel 37: 143-150.
123. Weiner AL, Sinnett K, Johnson S. 1995. Tack for intraocular drug delivery and method for inserting and removing the same. US Patent 5,466,233.
124. Varner SE, de Juan E, Jr., Shelley T, Barnes AC, Humayun M. 2004. Devices for intraocular drug delivery. US Patent 6,719,750.
125. Breton P, Guillon X, Roy D, Lescure F, Riess G, Bru N, Roques-Carmes C. 1998. Physico-chemical characterization, preparation and performance of poly(methylidene malonate 2.12) nanoparticles. Biomaterials 19:271-281. (Pubitemid 28239488)
126. Chan V, Liu KK, Le Visage C, Ju BF, Leong KW. 2004. Bioadhesive characterization of poly(methylidene malonate 2.12) microparticles on model extracellular matrix. Biomaterials 25:4327-4332. (Pubitemid 38388594)
127. Roy D, Guillon X, Lescure F, Couvreur P, Bru N, Breton P. 1997. On shelf stability of freeze-dried poly(methylidene malonate 2.12) nanoparticles. Int J Pharm 148:165-175. (Pubitemid 27160974)
128. Breton P, Roy D, Marchal-Heussler L, Seguin C, Couvreur P, Lescure F. 1994. In: Gregoriadis G, McCormack B, Poste G, editors. New poly(methylidene malonate 2.1.2) nanoparticles: Recent developments. In: Targeting of Drugs, 4. Advances in System ConstructsNATO ASI series, Series A: Life Sciences Vol. 273, Plenum Press, New York, pp. 161-172.
129. Lescure F, Seguin C, Breton P, Bourrinet P, Roy D, Couvreur P. 1994. Preparation and characterization of novel poly(- methylidene malonate 2.12)-made nanoparticles. Pharm Res 11:1270-1277. (Pubitemid 24287405)
130. Felt-Baeyens O, Eperon S, Morab P, Limal D, Sagodira S, Breton P, Simonazzi B, Bossy-Nobs L, Guex-Crosier Y. 2006. Biodegradable scleral implants as new triamcinolone acetonide delivery systems. Int J Pharm 322:6-12. (Pubitemid 44348861)
131. Okabe K, Kimura H, Okabe J, Kato A, Kunou N, Ogura Y. 2003. Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest Ophthalmol Vis Sci 44: 2702-2707. (Pubitemid 36618433)
132. Michelson JB, Nozik RA. 1979. Experimental endophthalmitis treated with an implantable osmotic minipump. Arch Ophthalmol 97:1345-1346.
133. Eliason JA, Maurice DM. 1980. An ocular perfusion system. Invest Ophthalmol Vis Sci 19:102-105.
134. Miki K, Ohkuma H, Ryan SJ. 1984. A method for chronic drug infusion into the eye. Jpn J Ophthalmol 28:140-146. (Pubitemid 14122843)
135. Avitabile T, Marano F, Castiglione F, Bucolo C, Cro M, Ambrosio L, Ferrauto C, Reibaldi A. 2001. Biocompatibility and biodegradation of intravitreal hyaluronan implants in rabbits. Biomaterials 22:195-200.
136. Li SK, Jeong EK, Hastings MS. 2004. Magnetic resonance imaging study of current and ion delivery into the eye during transscleral and transcorneal iontophoresis. Invest Ophthalmol Vis Sci 45:1224-1231.
137. Eljarrat-Binstock E, Orucov F, Frucht-Pery J, Pe'er Jand Domb AJ. 2008. Methylprednisolone delivery to the back of the eye using hydrogel iontophoresis. J Ocul Pharmacol Ther 24:344-350.
138. Csaky KG. 2007. New developments In the transscleral delivery of ophthalmic agents. The profile of the drug being delivered is as important as the delivery method. Retina Today 32-33.
139. Velez G, Whitcup SM. 1999. New developments in sustained release drug delivery for the treatment of intraocular disease. Br J Ophthalmol 83:1225-1229. (Pubitemid 29511801)